Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer (cancer that hasn't spread far from the lung).
- You finished chemoradiation (platinum-based chemo and radiation) and your tumor either shrank or stayed the same.
- You are in good enough health to walk and do daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within safe ranges as checked by tests.
- You agree not to become pregnant or father a child during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial is for people with limited-stage small cell lung cancer who have finished chemoradiation and still have small amounts of cancer DNA in their blood (called MRD-positive). The study tests a new treatment strategy after chemoradiation, and it may help reduce the chance of the cancer coming back.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.